M&A news: GlaxoSmithKline has acquired Okairos, a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash.
Swiss-based Okairos, a private company, has developed a novel vaccine platform technology which is expected to play an important role in GlaxoSmithKline's development of new prophylactic vaccines as well as new classes of therapeutic vaccines as part of the M&A news deal.
Okairos’ technology complements GlaxoSmithKline's existing vaccine technology and expertise and will enable GlaxoSmithKline to continue its work developing the next generation of vaccines.
The M&A news deal also includes a small number of early stage assets.
Under the terms of the M&A news transaction, GlaxoSmithKline will take full ownership of the company and thus assume ownership of early stage assets for diseases such as respiratory syncytial virus, hepatitis C virus, malaria, tuberculosis, ebola and HIV, supplementing the company’s existing vaccines pipeline.
GlaxoSmithKline and the Okairos management team are committed to an innovative collaboration and will work together over the next few months as part of the M&A news deal to develop ways of working that will maintain the autonomy, spirit and agility of this unique small biotech firm which will be strengthened by the support and advantages that GlaxoSmithKline can provide.
Report: Partnering Deals and Alliances with GlaxoSmithKline
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity